<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02000128</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PD-BIA</org_study_id>
    <nct_id>NCT02000128</nct_id>
  </id_info>
  <brief_title>Fluid Management Guided by Bioimpedance Analysis in Peritoneal Dialysis(PD) Patients.</brief_title>
  <official_title>A Prospective, Randomized Controlled Study of Bioimpedance Analysis(BIA) Guided Fluid Management in Peritoneal Dialysis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Purpose: to investigate the effect of bioimpedance analysis(BIA) guided fluid
           management versus experiential way on clinical outcome in peritoneal dialysis patients.

        2. Design: prospective,randomized,controlled,single center study

        3. Study hypothesis: Patients on peritoneal dialysis are frequently hypervolemic, which is
           associated with increasing hazard of death and cardiovascular events. Bioimpedance
           analysis is a safe, and easy way, which appears to be more useful and sensitive than
           other techniques for assessing volume status in dialysis patients. Therefore we
           hypothesize that more concise and strict fluid management guided by BIA may help to
           improve patients' survival, decrease cardiovascular events and hospitalization rate.

        4. Objects: incident and prevalent patients with overhydration status.

             1. anticipated cases:240

             2. arms: all the patients are randomized into two arms.(BIA group/clinical group)

             3. observational time:12 months

        5. Primary Outcome: all cause mortality. Secondary Outcomes: technique survival,
           cardiovascular events, peritonitis, residual renal function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>all cause mortality;cardiovascular related mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>technique failure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>permanent hemodialysis transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>heart failure, myocardial infarction,angina, Percutaneous coronary stenting, coronary artery bypass grafting,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>hospitalization events due to overload; Non-PD related infection; PD related peritonitis; peripheral angiopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>residual renal function</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change of baseline residual renal function, measured as residual glomerular filtration rate(rGFR) and urine volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>bioimpedance monitoring group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients whose fluid status will be monitored and guided by bioimpedance analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clinical monitoring group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients whose fluid status will be monitored and guided by clinical experience</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bioimpedance monitoring</intervention_name>
    <arm_group_label>bioimpedance monitoring group</arm_group_label>
    <other_name>Multi-frequency bioelectrical impedance analysis</other_name>
    <other_name>Body Composition Analyzer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical monitoring</intervention_name>
    <description>clinical symptom and examination,such as edema, body weight, blood pressure, cardial function</description>
    <arm_group_label>clinical monitoring group</arm_group_label>
    <other_name>routine method of assessing water status</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who are undergoing peritoneal dialysis and clinically stable for at least 3
             months;

          -  18 Years and older;

          -  ratio extracellular water (ECW)/total body water(TBW)â‰§0.4;

          -  signed the informed consent

        Exclusion Criteria:

          -  patients who have mental graft;

          -  amputation;

          -  patients who is unable to accomplish the BIA measurement in standing position for 3
             minutes;

          -  patients whose heart function are class IV estimated by New York Heart Association
             (NYHA) standard;

          -  Patients who have acute complications within 30 days prior to study enrollment;

          -  patients whose life expectancy is within 6 months;

          -  patients who are pregnant;

          -  patients who are unable to give consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuqing Yu, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xueqing Yu, MD,PHD</last_name>
    <phone>8620-87766335</phone>
    <phone_ext>8620-87769673</phone_ext>
    <email>yuxq@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuqing Yu, MD,PHD</last_name>
      <phone>8620-87766335</phone>
      <phone_ext>8620-87769673</phone_ext>
      <email>yuxq@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xue Qing Yu</investigator_full_name>
    <investigator_title>Director, Institute of Nephrology, Sun Yat-sen University</investigator_title>
  </responsible_party>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>fluid overload</keyword>
  <keyword>bioimpedance analysis</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
